medigraphic.com
ISSN 2007-8560 (Print)
Órgano Oficial de Difusión Científica de la Federación Mexicana de Colegios de Ortopedia y Traumatología, A.C. (FEMECOT)

2024, Number 4

<< Back Next >>

Ortho-tips 2024; 20 (4)

Giant cell bone tumor, treatment and diagnosis: literature review

Aragón DR, Rivera SG

Language: Spanish
References: 88
Page: 262-272
PDF size: 352.69 Kb.


ABSTRACT

The giant cell tumor (GCT) has a very versatile variety from the clinical presentation in gender and age group to its degree of malignancy, becoming fatal; radiographic classification is appropriate to determine the prognosis. Determining the histopathological diagnosis, which is currently the gold standard, is a pillar for treatment. Medical treatment from monoclonal antibodies for inoperable patients or degree of metastasis against the receptor for nuclear factor-κB ligand (RANKL) to reduce the size of the tumor and make it operable is the key in this. Other treatments such as embolization, laser photoablation, zolendronic acid, bisphosphonates or even adjuvants to surgical treatment such as liquid nitrogen and ethanol at the time of curettage are options for this pathology. The objective of this review is to determine the current epidemiology, classification, pathophysiology, clinical picture, diagnosis, medical and surgical treatment in order to have an overview and guide in the follow-up of this pathology.


REFERENCES

  1. Hakim DN, Pelly T, Kulendran M, Caris JA. Benign tumours of the bone: a review. J Bone Oncol. 2015; 4(2): 37-41.

  2. Mavrogenis AF, Igoumenou VG, Megaloikonomos PD, Panagopoulos GN, Papagelopoulos PJ, Soucacos PN. Giant cell tumor of bone revisited. SICOT J. 2017; 3: 54.

  3. DelaGarza-Montano P, Estrada-Villasenor E, Dominguez-Rubio R, Martinez-Lopez V, Avila-Luna A, Alfaro-Rodriguez A, et al. Epidemiological aspects of osteosarcoma, giant cell tumor and chondrosarcoma musculoskeletal tumors-experience of the National Rehabilitation Institute, Mexico City. Asian Pac J Cancer Prev. 2015; 16 (15): 6451-6455.

  4. Estrada-Villaseñor EG, Linares-González LM, Delgado-Cedillo EA, et al. Prevalencia y características clínico-patológicas del tumor de células gigantes. Acta Ortop Mex. 2015; 29 (6): 295-298.

  5. Lin F, Hu Y, Zhao L, Zhang H, Yu X, Wang Z, et al. The epidemiological and clinical features of primary giant cell tumor around the knee: A report from the multicenter retrospective study in china. J Bone Oncol. 2016; 5 (1): 38-42.

  6. Júnior RC, Pereira MG, Garcia PB, Santos PA, Cavalcanti-Ados S, Meohas W. Epidemiological study on giant cell tumor recurrence at the Brazilian National Institute of Traumatology and Orthopedics. Rev Bras Ortop. 2016; 51 (4): 459-465.

  7. de Carvalho Diniz Ferraz DF, Torres Dos Santos CA, Farias Costa VH, Gonçalves Souza AM, Gomes Lima PR. Giant-cell tumor: analysis on the importance of early diagnosis and the epidemiological profile. Rev Bras Ortop. 2016; 51 (1): 58-62.

  8. Georgiev GP, Slavchev S, Dimitrova I, Landzhov B. Giant cell tumor of bone: current review of morphological, clinical, radiological, and therapeutic characteristics. J Clin Exp Invest. 2014; 5 (3).

  9. Jaffe HL. Giant-cell tumour (osteoclastoma) of bone: its pathologic delimitation and the inherent clinical implications. Ann R Coll Surg Engl. 1953; 13 (6): 343-355.

  10. Baptista AM, Camargo AFF, Caiero MT, Rebolledo DCS, Correia LFM, Camargo OP. GCT: what happened after 10 years of curettage and cement? retrospective study of 46 cases. acta ortopédica brasileira: 2014; 22 (6): 308-311.

  11. Saxena CC, Safaya R, Kawatra Madan N, Khan SA, Iyer VK. Histopathological, immunohistochemical, and image analytic parameters characterizing the stromal component in primary and recurrent giant cell tumor of bone. J Clin Orthop Trauma. 2016; 7 (2): 109-114.

  12. Comunoglu N, Kepil N, Dervisoglu S. Histopathology of giant cell tumors of the bone: With special emphasis on fibrohistiocytic and aneurysmal bone cyst like components. Acta Orthop Traumatol Turc. 2019; 53 (1): 35-39.

  13. Charles JF, Aliprantis AO. Osteoclasts: more than "bone eaters". Trends Mol Med. 2014; 20 (8): 449-459.

  14. Boyce BF, Xing L. The RANKL/RANK/OPG pathway. Curr Osteoporos Rep. 2007; 5 (3): 98-104.

  15. Maruyama K, Takada Y, Ray N, Kishimoto Y, Penninger JM, Yasuda H, et al. Receptor activator of NF-kappa B ligand and osteoprotegerin regulate proinflammatory cytokine production in mice. J Immunol. 2006; 177 (6): 3799-3805.

  16. Mizukami J, Takaesu G, Akatsuka H, Sakurai H, Ninomiya-Tsuji J, Matsumoto K, et al. Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol Cell Biol. 2002; 22 (4): 992-1000.

  17. Dietrich MF, Cavuoti D, Landay M, Arriaga YE. Histological regression of giant cell tumor of bone following RANK ligand inhibition. J Investig Med High Impact Case Rep. 2014; 2 (4): 2324709614560216.

  18. Liu JX, Zhang ZC, Shao ZW, Pu FF, Wang BC, Zhang YK, et al. TRAIL-R1 as a novel surface marker for circulating giant cell tumor of bone. Oncotarget. 2017; 8 (31): 50724-50730.

  19. Yalcinkaya U, Ugras N, Kabul S, Ocakoglu G, Bilgen MS. Prognostic value of p53 protein expression in giant cell tumor of bone. Pol J Pathol. 2015; 66 (4): 389-396.

  20. Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013; 45 (12): 1479-1482.

  21. Edwards PC. Insight into the pathogenesis and nature of Central Giant Cell Lesions of the Jaws. Med Oral Patol Oral Cir Bucal. 2015; 20 (2): e196-198.

  22. Sarungbam J, Agaram N, Hwang S, Lu C, Wang L, Healey J, et al. Symplastic/pseudoanaplastic giant cell tumor of the bone. Skeletal Radiol. 2016; 45 (7): 929-935.

  23. Kato-Kaneko M, Liu X, Oki H, Ogasawara S, Nakamura T, Saidoh N, et al. Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone. Cancer Sci. 2014; 105 (6): 744-748.

  24. Al-Abbadi MA, Al-Yousef MJ, Yousef MM, Sheikh SS, Almasri NM, Amr SS. CD10 and CD138 can be expressed in giant cell tumor of bone: An immunohistochemical study. Avicenna J Med. 2016; 6 (3): 69-74.

  25. Lehner B, Kunz P, Saehr H, Fellenberg J. Epigenetic silencing of genes and microRNAs within the imprinted Dlk1-Dio3 region at human chromosome 14.32 in giant cell tumor of bone. BMC Cancer. 2014; 14: 495.

  26. Li C, Zheng X, Ghert M, Li H, Wang B, Feng Y. Expressions and clinical significance of factors related to giant cell tumor of bone. Int J Clin Exp Med. 2015; 8 (12): 22509-22514.

  27. Zhang J, Dong J, Yang Z, Ma X, Zhang J, Li M, et al. Expression of ezrin, CD44, and VEGF in giant cell tumor of bone and its significance. World J Surg Oncol. 2015; 13: 168.

  28. Prashant K, Bhattacharyya TD, Frank H, Ram P. An unusual case of giant cell tumor of first metatarsal: a rare case report and review of literature. J Orthop Case Rep. 2016; 6 (5): 3-6.

  29. Savvidou OD, Mavrogenis AF, Sakellariou VI, Chloros GD, Sarlikiotis T, Papagelopoulos PJ. Extra-articular diffuse giant cell tumor of the tendon sheath: a report of 2 cases. Arch Bone Jt Surg. 2016; 4 (3): 273-276.

  30. van der Heijden L, Dijkstra PD, van de Sande MA, Kroep JR, Nout RA, van Rijswijk CS, et al. The clinical approach toward giant cell tumor of bone. Oncologist. 2014 May;19(5):550-561.

  31. Fotiadis E, Papadopoulos A, Svarnas T, Akritopoulos P, Sachinis NP, Chalidis BE. Giant cell tumour of tendon sheath of the digits. A systematic review. Hand (N Y). 2011; 6 (3): 244-249.

  32. Rivera-Saldívar G, Torres-González R, Fuentes-Figueroa S, Técualt-Gómez R, Amaya-Zepeda RA, Guevara-López U. Caracterización del dolor de la rodilla con patología oncológica. Cir Cir. 2012; 80 (6): 536-542.

  33. Burke C, Link T, O'Donnell RJ, Cho SJ, Motamedi D. Giant cell tumor of bone: documented progression over 4 years from its origin at the metaphysis to the articular surface. Case Rep Radiol. 2016; 2016: 9786925.

  34. Futamura N, Urakawa H, Tsukushi S, Arai E, Kozawa E, Ishiguro N, et al. Giant cell tumor of bone arising in long bones possibly originates from the metaphyseal region. Oncol Lett. 2016 Apr;11(4):2629-2634.

  35. Sharma V, Sharma S, Mistry KA, Awasthi B, Verma L, Singh U. Giant cell tumor of bone in skeletally immature patients - a clinical perspective. J Orthop Case Rep. 2015; 5 (4): 57-60.

  36. Strom TM, Skeie AT, Lobmaier IK, Zaikova O. Giant cell tumor: a rare condition in the immature skeleton-a retrospective study of symptoms, treatment, and outcome in 16 children. Sarcoma. 2016; 2016: 3079835.

  37. Liu C, Tang Y, Li M, Jiao Q, Zhang H, Yang Q, et al. Clinical characteristics and prognoses of six patients with multicentric giant cell tumor of the bone. Oncotarget. 2016; 7 (50): 83795-83805.

  38. Wirbel R, Blümler F, Lommel D, Syré G, Krenn V. Multicentric giant cell tumor of bone: synchronous and metachronous presentation. Case Rep Orthop. 2013; 2013: 756723.

  39. Liu J, Yang H, Sun R, Yang Z, Zhu Z. Retrospective analysis of patients with rare-site and metastatic giant cell tumor. Chin J Cancer Res. 2013; 25 (5): 585-592.

  40. Cañete AN, Bloem HL, Kroon HM. Primary bone tumors of the spine. Radiologia. 2016; 58 Suppl 1: 68-80.

  41. Zhang J, Li Y, Li D, Xia J, Li S, Yu S, et al. Clinical effects of three surgical approaches for a giant cell tumor of the distal radius and ulna. Mol Clin Oncol. 2016; 5 (5): 613-617.

  42. Briet JP, Becker SJ, Oosterhoff TCh, Ring D. Giant cell tumor of tendon sheath. Arch Bone Jt Surg. 2015; 3 (1): 19-21.

  43. Sasaki H, Nagano S, Shimada H, Yokouchi M, Setoguchi T, Ishidou Y, et al. Diagnosing and discriminating between primary and secondary aneurysmal bone cysts. Oncol Lett. 2017; 13 (4): 2290-2296.

  44. Rendina D, De Filippo G, Ralston SH, Merlotti D, Gianfrancesco F, Esposito T, et al. Clinical characteristics and evolution of giant cell tumor occurring in Paget's disease of bone. J Bone Miner Res. 2015; 30 (2): 257-263.

  45. Yang Y, Huang Z, Niu X, Xu H, Li Y, Liu W. Clinical characteristics and risk factors analysis of lung metastasis of benign giant cell tumor of bone. J Bone Oncol. 2017; 7: 23-28.

  46. Ueda T, Morioka H, Nishida Y, Kakunaga S, Tsuchiya H, Matsumoto Y, et al. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial. Ann Oncol. 2015; 26 (10): 2149-2154.

  47. Gaston CL, Grimer RJ, Parry M, Stacchiotti S, Dei Tos AP, Gelderblom H, et al. Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. Clin Sarcoma Res. 2016; 6 (1): 15.

  48. Tanaka T, Slavin J, McLachlan SA, Choong P. Anti-osteoclastic agent, denosumab, for a giant cell tumor of the bone with concurrent Paget's disease: A case report. Oncol Lett. 2017; 13 (4): 2105-2108.

  49. Kajiwara D, Kamoda H, Yonemoto T, Iwata S, Ishii T, Tsukanishi T, et al. Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor. Asian Spine J. 2016; 10 (3): 553-557.

  50. Bardakhchyan S, Kager L, Danielyan S, Avagyan A, Karamyan N, Vardevanyan H, et al. Denosumab treatment for progressive skull base giant cell tumor of bone in a 14 year old female - a case report and literature review. Ital J Pediatr. 2017; 43 (1): 32.

  51. Yamagishi T, Kawashima H, Ogose A, Ariizumi T, Sasaki T, Hatano H, et al. Receptor-activator of nuclear KappaB ligand expression as a new therapeutic target in primary bone tumors. PLoS One. 2016; 11 (5): e0154680.

  52. Deveci MA, Paydas S, Gonlüsen G, Ozkan C, Bicer OS, Tekin M. Clinical and pathological results of denosumab treatment for giant cell tumors of bone: prospective study of 14 cases. Acta Orthop Traumatol Turc. 2017; 51 (1): 1-6.

  53. Singh AS, Chawla NS, Chawla SP. Giant-cell tumor of bone: treatment options and role of denosumab. Biologics. 2015; 9: 69-74.

  54. López-Pousa A, Martín-Broto J, Garrido T, Vázquez J. Giant cell tumour of bone: new treatments in development. Clin Transl Oncol. 2015; 17 (6): 419-430.

  55. Hakozaki M, Tajino T, Yamada H, Hasegawa O, Tasaki K, Watanabe K, et al. Radiological and pathological characteristics of giant cell tumor of bone treated with denosumab. Diagn Pathol. 2014; 9: 111.

  56. Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SP, Pienkowski A, et al. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol. 2015; 22 (9): 2860-2868.

  57. Xu L, Luo J, Jin R, Yue Z, Sun P, Yang Z, et al. Bortezomib inhibits giant cell tumor of bone through induction of cell apoptosis and inhibition of osteoclast recruitment, giant cell formation, and bone resorption. Mol Cancer Ther. 2016; 15 (5): 854-865.

  58. Shibuya I, Takami M, Miyamoto A, Karakawa A, Dezawa A, Nakamura S, et al. In Vitro study of the effects of denosumab on giant cell tumor of bone: comparison with zoledronic acid. Pathol Oncol Res. 2019; 25 (1): 409-419.

  59. Yang T, Zheng XF, Li M, Lin X, Yin QS. Stimulation of osteogenic differentiation in stromal cells of giant cell tumour of bone by zoledronic acid. Asian Pac J Cancer Prev. 2013; 14 (9): 5379-5383.

  60. Nishimura S, Hashimoto K, Tan A, Yagyu Y, Akagi M. Successful treatment with denosumab in a patient with sacral giant cell tumor of bone refractory to combination therapy with arterial embolization and zoledronic acid: a case report. Mol Clin Oncol. 2017; 6 (3): 307-310.

  61. Gao ZH, Yin JQ, Xie XB, Zou CY, Huang G, Wang J, et al. Local control of giant cell tumors of the long bone after aggressive curettage with and without bone cement. BMC Musculoskelet Disord. 2014; 15: 330.

  62. Jha R, Sharma R, Rastogi S, Khan SA, Jayaswal A, Gamanagatti S. Preoperative embolization of primary bone tumors: a case control study. World J Radiol. 2016; 8 (4): 378-389.

  63. Martínez-Estrada JG, Santamaría-Bahena O. Reemplazo articular en tumor de células gigantes. Reporte de ocho casos. Acta Ortop Mex. 2016; 30 (5): 241-245.

  64. Zhang S, Zhang J, Wang X. Comparison of tumor curettage and resection for treatment of giant cell tumor of the bone around the knee joint. Pak J Med Sci. 2016; 32 (3): 662-666.

  65. Saibaba B, Chouhan DK, Kumar V, Dhillon MS, Rajoli SR. Curettage and reconstruction by the sandwich technique for giant cell tumours around the knee. J Orthop Surg (Hong Kong). 2014; 22 (3): 351-355.

  66. Gupta SP, Garg G. Curettage with cement augmentation of large bone defects in giant cell tumors with pathological fractures in lower-extremity long bones. J Orthop Traumatol. 2016; 17 (3): 239-247.

  67. Nithyananth M, Priscilla AJ, Boopalan PV, Titus VT, Lee VN. Time required for effective action of phenol against giant cell tumour cells. J Orthop Surg (Hong Kong). 2014; 22 (1): 104-107.

  68. Rigollino AV, Fernando TS, Tanaka MH, Souza MM. Giant cell tumor locally advanced around the knee: treatment and literature review. Rev Bras Ortop. 2017; 52 (4): 473-478.

  69. Zheng K, Yu XC, Hu YC, Wang Z, Wu SJ, Ye ZM, et al. How to fill the cavity after curettage of giant cell tumors around the knee? A multicenter analysis. Chin Med J (Engl). 2017; 130 (21): 2541-2546.

  70. Dabak N, Gocer H, Cirakli A. Advantages of pressurized-spray cryosurgery in giant cell tumors of the bone. Balkan Med J. 2016; 33 (5): 496-503.

  71. Sun S, Zhang Q, Zhao CS, Cai J. Long-term outcomes of ultrasonic scalpel treatment in giant cell tumor of long bones. Oncol Lett. 2014; 8 (1): 145-150.

  72. Müller DA, Beltrami G, Scoccianti G, Campanacci DA, Franchi A, Capanna R. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series. World J Surg Oncol. 2016; 14 (1): 281.

  73. Yacob O, Umer M, Gul M, Qadir I. Segmental excision versus intralesional curettage with adjuvant therapy for giant cell tumour of bone. J Orthop Surg (Hong Kong). 2016; 24 (1): 88-91.

  74. Moon MS, Kim SS, Moon JL, Kim SS, Moon H. Treating giant cell tumours with curettage, electrocautery, burring, phenol irrigation, and cementation. J Orthop Surg (Hong Kong). 2013; 21 (2): 209-212.

  75. Li X, Xu Y, Zhu Y, Xu X. Surgical treatment for diffused-type giant cell tumor (pigmented villonodular synovitis) about the ankle joint. BMC Musculoskelet Disord. 2017; 18 (1): 450.

  76. Fuchs DJ, Switaj PJ, Peabody TD, Kadakia AR. Tenosynovial giant cell tumor in the midfoot treated with femoral head allograft reconstruction. J Foot Ankle Surg. 2018; 57 (1): 172-178.

  77. Mozaffarian K, Modjallal M, Vosoughi AR. Treatment of giant cell tumor of distal radius with limited soft tissue invasion: curettage and cementing versus wide excision. J Orthop Sci. 2018; 23 (1): 174-179.

  78. Meena DK, Thalanki S, Sharma SB. Wrist fusion through centralisation of the ulna for recurrent giant cell tumour of the distal radius. J Orthop Surg (Hong Kong). 2016; 24 (1): 84-87.

  79. Kamal AF, Simbolon EL, Prabowo Y, Hutagalung EU. Wide resection versus curettage with adjuvant therapy for giant cell tumour of bone. J Orthop Surg (Hong Kong). 2016; 24 (2): 228-231.

  80. Takeuchi A, Tsuchiya H, Ishii T, Nishida Y, Abe S, Matsumine A, et al. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study. BMC Musculoskelet Disord. 2016; 17: 306.

  81. Cheng DD, Hu T, Zhang HZ, Huang J, Yang QC. Factors affecting the recurrence of giant cell tumor of bone after surgery: a clinicopathological study of 80 cases from a single center. Cell Physiol Biochem. 2015; 36 (5): 1961-1970.

  82. Xu L, Jin J, Hu A, Xiong J, Wang D, Sun Q, et al. Soft tissue recurrence of giant cell tumor of the bone: Prevalence and radiographic features. J Bone Oncol. 2017; 9: 10-14.

  83. Gouin F, Dumaine V; French Sarcoma and Bone Tumor Study Groups GSF-GETO. Local recurrence after curettage treatment of giant cell tumors in peripheral bones: retrospective study by the GSF-GETO (French Sarcoma and Bone Tumor Study Groups). Orthop Traumatol Surg Res. 2013; 99 (6 Suppl): S313-S318.

  84. Li D, Zhang J, Li Y, Xia J, Yang Y, Ren M, et al. Surgery methods and soft tissue extension are the potential risk factors of local recurrence in giant cell tumor of bone. World J Surg Oncol. 2016; 14: 114.

  85. Hu P, Zhao L, Zhang H, Yu X, Wang Z, Ye Z, et al. Recurrence rates and risk factors for primary giant cell tumors around the knee: a multicentre retrospective study in China. Sci Rep. 2016; 6: 36332.

  86. Siddiqui MA, Seng C, Tan MH. Risk factors for recurrence of giant cell tumours of bone. J Orthop Surg (Hong Kong). 2014; 22 (1): 108-110.

  87. Hu Y, Zhao L, Zhang H, Yu X, Wang Z, Ye Z, et al. Sex differences in the recurrence rate and risk factors for primary giant cell tumors around the knee in China. Sci Rep. 2016; 6: 28173.

  88. Muheremu A, Niu X. Pulmonary metastasis of giant cell tumor of bones. World J Surg Oncol. 2014; 12: 261.




2020     |     www.medigraphic.com